The incidence of adverse events was comparable among groups. Conclusions: 24-week oltipraz treatment was well tolerated and significantly reduced liver fat amount and BMI without worsening

of liver fibrosis in patients with NAFLD (NCT01373554). Disclosures: The following people have nothing to disclose: Won Kim, June Sung Lee, Chun Kyon Lee, Jong Eun Yeon, Byeong Gwan Kim, Yoon Jun Kim Nonalcoholic steatohepatitis (NASH) is associated with dys-lipidemia and cardiovascular disease (CVD). However, the impact of NASH resolution on dyslipidemia is unknown. Methods: Individuals in the Pioglitazone vs. Vitamin E vs. Placebo for the Treatment of Nondiabetic Patients with NASH (PIVENS) trial were included. In the PIVENS trial individuals were randomized

to pioglitazone, vitamin E or placebo daily. Change in lipid levels Copanlisib purchase was compared between those with and without NASH resolution. Results: Dyslipidemia was frequent, with low high-density lipoprotein (HDL) (<40mg/dL men, <50 mg/dL women) in 63%, hypertriglyceridemia (≥150 mg/dL) in 46%, hypercholesterolemia (≥200 mg/dL) in 47%, and triglycerides (TG)/HDL>5.0 in 25%. Sixteen percent had LDL≥160 mg/dL and 73% had elevated non-HDL cholesterol (non-HDL-C) (≥130 mg/dL). Among 222 individuals, 77 (35%) had NASH resolution, including 33 (47%) on pioglitazone, 29 (36%) on vitamin E and 15 (21%) on placebo. HDL increased with NASH resolution but Compound Library supplier decreased in those without resolution (2.9mg/dL vs. -2.5mg/dL, P<0.001, Table). Those with NASH resolution had a significant decreases in TG and TG/HDL ratio compared to those without resolution (TG -21.1 vs. -2.3mg/dL, P=0.03 and TG/HDL -0.7 vs 0.1, P=0.003). Non-HDL-C, LDL and cholesterol decreased during the study in both groups but there was no difference between those with or without NASH resolution. Lipid 3-mercaptopyruvate sulfurtransferase changes did not vary by treatment. Conclusions: In the PIVENS trial, regardless of treatment group (pioglitazone, vitamin E, or placebo),

NASH resolution was associated with improvements in TG and HDL but not in LDL and non-HDL-C. Individuals whose NASH resolves after 96 weeks of follow-up may still be at risk for CVD. Changes in lipid profiles by NASH resolution Derived from multiple linear regression models, included treatment group, BMI, ethnicity, statin use during study; for change measures, baseline value of lipid. Disclosures: Kathleen Corey – Advisory Committees or Review Panels: Gilead Naga P. Chalasani – Consulting: Salix, Abbvie, Lilly, Boerhinger-Ingelham, Aege-rion; Grant/Research Support: Intercept, Lilly, Gilead, Cumberland, Galectin The following people have nothing to disclose: Raj Vuppalanchi, Laura Wilson, Oscar Cummings Introduction: NASH with fibrosis is a significant cause of liver disease in which effective therapies are limited. Galectin-3 is a critical protein in the pathogenesis of liver fibrogenesis and NASH.